Agilent Technologies (NYSE:A) Given New $165.00 Price Target at Citigroup

Agilent Technologies (NYSE:A - Get Free Report) had its price target upped by equities researchers at Citigroup to $165.00 in a report issued on Thursday, Stock Target Advisor reports. The firm currently has a "buy" rating on the medical research company's stock. Citigroup's target price would indicate a potential upside of 23.88% from the stock's previous close.

A has been the topic of a number of other reports. UBS Group raised their price target on shares of Agilent Technologies from $141.00 to $150.00 and gave the stock a "neutral" rating in a research report on Thursday, August 22nd. Evercore ISI lifted their price target on shares of Agilent Technologies from $135.00 to $145.00 and gave the company an "in-line" rating in a research report on Tuesday, October 1st. Sanford C. Bernstein reduced their price target on Agilent Technologies from $140.00 to $135.00 and set a "market perform" rating on the stock in a research report on Tuesday, November 26th. JPMorgan Chase & Co. lowered their price objective on Agilent Technologies from $165.00 to $160.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 26th. Finally, Barclays reduced their target price on Agilent Technologies from $145.00 to $135.00 and set an "underweight" rating on the stock in a report on Wednesday, November 27th. One analyst has rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Agilent Technologies presently has an average rating of "Hold" and a consensus price target of $143.62.

Agilent Technologies Stock Performance

NYSE:A traded up $0.18 during mid-day trading on Thursday, hitting $133.19. The stock had a trading volume of 2,166,453 shares, compared to its average volume of 1,726,255. Agilent Technologies has a twelve month low of $124.16 and a twelve month high of $155.35. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.58 and a current ratio of 2.09. The stock has a market cap of $38.27 billion, a price-to-earnings ratio of 30.13, a PEG ratio of 4.48 and a beta of 1.07. The company's 50 day simple moving average is $136.04 and its 200 day simple moving average is $136.41.

Agilent Technologies (NYSE:A - Get Free Report) last released its quarterly earnings data on Monday, November 25th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.41 by $0.05. The company had revenue of $1.70 billion during the quarter, compared to analysts' expectations of $1.67 billion. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. The business's revenue was up .8% on a year-over-year basis. During the same period last year, the firm posted $1.38 earnings per share. On average, equities research analysts forecast that Agilent Technologies will post 5.56 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP Dominique Grau sold 9,990 shares of the company's stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the transaction, the senior vice president now owns 40,011 shares of the company's stock, valued at $5,801,595. This represents a 19.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 0.33% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of A. Livelsberger Financial Advisory acquired a new stake in shares of Agilent Technologies during the third quarter worth $28,000. Crewe Advisors LLC raised its position in shares of Agilent Technologies by 114.8% in the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company's stock worth $25,000 after acquiring an additional 101 shares in the last quarter. Ashton Thomas Securities LLC acquired a new position in shares of Agilent Technologies in the 3rd quarter valued at about $31,000. Ridgewood Investments LLC bought a new stake in shares of Agilent Technologies during the 2nd quarter valued at about $29,000. Finally, Fortitude Family Office LLC grew its stake in Agilent Technologies by 68.3% during the third quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company's stock worth $35,000 after purchasing an additional 95 shares during the period. 87.42% of the stock is owned by institutional investors and hedge funds.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.